PCT/GB 95 / 01107

08 / 737457

REC'D 15 JUN 1995

WIPO PCT

The Patent Office

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

I, the undersigned, being an officer duly authorised in accordance with Section 62(3) of the Patents and Designs Act 1907, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the Patent application identified therein.

I also certify that the attached copy of the Request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

I also certify that by virtue of an assignment registered under the Patents Act 1977, the application is now proceeding in the name as substituted.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed W. Lunell

Dated 07 JUN 1995

PRIORITY DOCUMENT

C.S.1.

No. GB 9122643.5

By virtue of a direction given under Section 30 of the Patents Act, 1977, the application is proceeding in the name of

FC HAGEN LIMITED
ABERDEEN BUSINESS CENTRE
WILLOWBANK HOUSE
WILLOWBANK ROAD
ABERDEEN
AB1 2YG.

Printed in the UK by HMSO Basildon 277801/K28863 3m 6/91 ATP

PCT/GB 95/0110

For official use

18MAY94#00257621 FAT 1 77 UC 35.00

13 MAY 1994

Your reference
HCM/MJL/C734/C

9409643.5

The Patent Office — Request for grant of a Patent

Form 1/77

Patents Act 1977

Notes
Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071–438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

❷ Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

13 MAY 1994

Warning
After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

❶ Title of invention

1 Please give the title of the invention: Recombinant Antibodies for Delivery of Immunodominant Peptides

❷ Applicant's details

☐ **First or only applicant**

2a If you are applying as a corporate body please give:

Corporate name

Country *(and State of incorporation, if appropriate)*

SECTION 30 (1977 Act) APPLICATION FILED 20.3.95

2b If you are applying as an individual or one of a partnership please give in full:

Surname: CARDY

Forenames: Donald Leonard Nicholas

2c **In all cases**, please give the following details:

Address: c/o Eclagen
Aberdeen Business Centre
Willowbank House
Willowbank Road
Aberdeen

UK postcode *(if applicable)*: AB1 2YG

Country: United Kingdom

ADP number *(if known)*: 06558324001 KAM

2d, 2e and 2f: *If there are further applicants please provide details on a separate sheet of paper.*

Second applicant *(if any)*

2d If you are applying as a corporate body please give

Corporate name

Country *(and State of incorporation, if appropriate)*

2e If you are applying as an individual or one of a partnership please give in full.

Surname

Forenames

2f **In all cases**, please give the following details

Address

UK postcode *(if applicable)*

Country

ADP number *(if known)*

❸ *An address for service in the United Kingdom must be supplied*

Please mark correct box

❸ Address for service details

3a Have you appointed an agent to deal with your application?

Yes [X] No [ ] ➡ ***go to 3b***

↓ ***please give details below***

Agent's name Keith W Nash & Co

Agent's address Pearl Assurance House
90-92 Regent Street
Cambridge

Postcode CB2 1DP

Agent's ADP number 1206001

3b: *If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.*

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Daytime telephone number *(if available)*

Postcode

ADP number *(if known)*

❹ Reference number

4 Agent's or applicant's reference number *(if applicable)* HCM/MJL/C734/C

❺ Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Please mark correct box

Yes ☐ No ☒ ➡ ***go to 6***

↓ ***please give details below***

❑ number of earlier application or patent number

❑ filing date

(day month year)

❑ and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

❻ Declaration of priority

❻ If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number *(if known)*	Filing date *(day, month, year)*

❼ *The answer must be 'No' if*
- *any applicant is not an inventor*
- *there is an inventor who is not an applicant, or*
- *any applicant is a corporate body.*

❼ Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes [ ] No [X] ➡ ***A Statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).***

❽ *Please supply duplicates of claim(s), abstract, description and drawing(s).*

❽ Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77			
Claim(s)		Description	12
Abstract		Drawing(s)	3

8b Which of the following documents also accompanies the application?

Please mark correct box(es)

Priority documents *(please state how many)*	
Translation(s) of Priority documents *(please state how many)*	
Patents Form 7/77 – Statement of Inventorship and Right to Grant *(please state how many)*	
Patents Form 9/77 – Preliminary Examination/Search	
Patents Form 10/77 – Request for Substantive Examination	

❾ *You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.*

❾ Request

I/We request the grant of a patent on the basis of this application.

Please sign here ➡ Signed Keith W. Nash & Co Date 13 / 5 / 94 (day / month / year)

Keith W Nash & Co

A completed fee sheet should preferably accompany the fee.

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either:

❑ ***The Comptroller***
The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

or

❑ ***The Comptroller***
The Patent Office
25 Southampton Buildings
London
WC2A 1AY

Title: Recombinant Antibodies for Delivery of Immunodominant Peptides

The invention relates to a new type of recombinant antibody designed for the efficient delivery of one or more immunodominant (antigenic) peptide molecules to a target cell for subsequent antigen presentation by the target cell and either induction or inhibition of an immune response. In particular, the invention relates to antibody molecules containing immunodominant peptide sequences whereby these antibody molecules enter cells via internalising antigens and are subsequently processed into peptides for antigen presentation. The invention also relates to recombinant antibodies modified in order to facilitate the attachment of immunodominant peptides for delivery into the target cell. The invention also relates to methods for treatment and prevention of disease using these new types of recombinant antibody and methods for generating these antibodies.

The finding that T-cells recognise antigen as peptides bound to major histocompatibility complex (MHC) molecules has given rise to attempts to use defined synthetic peptides corresponding to immunodominant T-cell epitopes to either activate or tolerise T-cells to specific antigens. Invariably, the approach used has been to immunise with the immunogenic peptide in order to induce a T-cell response relying on the efficient processing and antigen presentation by professional immune system cells to induce a T-cell response comprising either a predominant response by CD8+ cytotoxic T lymphocytes (CTLs) for peptide presented in conjunction with MHC class I molecules or a predominant CD4+

helper T-cell response for peptide presented in conjunction with MHC class II molecules. For the treatment of cancer, there is now a major interest in the induction (or adoptive transfer) of CTLs specific for tumour-associated antigens such as the MAGE-1 antigen produced by a high proportion of human melanoma tumours (van der Bruggen et al., Science 254 (1991) p1643). There is also an interest in the identification of peptides associated with diseases such as autoimmunity in order to induce tolerance by administration of the autoimmune peptide and subsequent presentation and overstimulation leading to abrogation of peptide-specific CTLs (e.g. Aichele et al., PNAS 91 (1994) p444). Another approach is to immunise with altered peptides which, upon presentation, can bind to but not activate a specific T-cell thus antagonising deleterious responses of such T-cells, for example to superantigens critical to the infectious action of a number of bacteria and viruses via activation of specific T helper cells (e.g. Evavold et al., PNAS 91 (1994) p2300).

There are 3 main limitations to the direct use of peptides for activation or tolerance of specific T-cells to antigens involved in disease processes. Firstly, peptide-induced activation of cytotoxic T cells for the subsequent destruction of aberrant disease-associated target cells is restricted to target cells which present the specific peptide, usually professional (constitutive) or facultative antigen presenting cells and also cells such as cancer cells expressing the MAGE-1 antigen. Thus, it is currently not possible to direct the activation of T cells by antigen presentation by specifically chosen cell types. Secondly, peptide-induced activation or tolerance relies on the efficient uptake and presentation of peptide

by professional or facultative antigen presenting cells; the efficiency of presentation is highly dependent on factors such as peptide concentration and peptide formulation with adjuvants which are variable for different peptides and do not always result in a specific T-cell response. Thirdly, peptide presentation is MHC-restricted and dependent on specific HLA type and thus the activation or tolerance of T cells to a certain immunodominant peptide is dependent on the HLA type of the individual.

Instead of relying on individual peptides finding and being presented by professional or facultative antigen-presenting cells, the present invention uses antibody molecules specific for internalising antigens on any cell type to deliver one or more peptides internally to these cells. Upon digestion and processing of the antibody-peptide molecule, the peptides can then be presented in the presence of appropriate MHC molecules. Specifically, the present invention relates to a new class of antibody molecules produced, by recombinant DNA methods, to include preferably within the protein the sequence of one or more immunodominant peptides, or to alternatively include modifications specifically for the efficient attachment of one or more peptide molecules. Thus the invention provides, for the first time, a means of targeting antigen presentation to a particular chosen cell with the main requirement of an internalising antigen recognised by an antibody containing the peptide antigen to be presented (optimally in multiple copies).

Advantages of the present invention for the activation or tolerance of T-cells are

several-fold. Firstly, by using an antibody to deliver immunodominant peptides, these peptides can be delivered, via an internalising antigen, to cells which do not normally present such peptides. In the case of cancer cells for example, a cancer cell can then present one or more peptides designed to activate CTLs subsequently to destroy the cancer cell. In the case of normal cells subject to autoimmune destruction by CTLs, these peptides can be delivered via an internalising antigen either as high doses of normal immunodominant peptides to induce tolerance by abrogation of the usually destructive CTLs or as altered peptides which antagonise the disease-associated T-cell activation. Secondly, several different peptide sequences or multiple copies of the same peptide sequence can be associated with a single antibody molecule, the former providing the prospect for a choice of peptides for presentation by the appropriate MHC haplotype in the individual immunised and the latter providing the prospect for efficiently delivering a high dose of peptide via multiple copies on the antibody molecule. Thirdly, by using an antibody to deliver immunodominant peptides, these peptides can be efficiently delivered, via an internalising antigen, to specific professional antigen presenting cells as an alternative to the less specific endocytosis by these cells; thus, the presentation of antigens can be more focused in order to control better the type of immune response to the immunodominant peptide.

It will be understood that the present invention can apply to both class-I and class-II MHC-restricted immunodominant peptides and can potentially be applied to the targeted induction of an immune response to many different antigens in

many different disease states such as cancer (induction of CTLs by cancer cells), autoimmunity (antagonism of T-cell activation or induction of tolerance), infection (induction of CTLs by infected cells, antagonism of T helper cell activation by superantigens) and inflammation (antagonism of T-cell activation). It will also be understood that antibodies produced by the present invention could include the so-called "universal" immunodominant peptides (e.g. tetanus toxin peptides) against which a high proportion of individuals might already be sensitised to by vaccination. It will also be understood that antibodies produced by the present invention could include a mixture of different peptides which associate with different MHC class-I or class-II molecules thus providing for a broader prospect of inducing an immune response in different population groups carrying different HLA types. It will also be understood that the antibodies of the present invention could be used in several different ways in disease treatment and prevention including to deliver peptides *ex vivo* for the induction of CTLs prior to adoptive immunotherapy and to enhance the T-cell activating, blocking or abrogating ability of cells already presenting the specific peptide(s) or analogues thereof. It will be understood that antibodies of the present invention could be targeted to professional antigen presenting cells such as, for example, macrophages (e.g. via the FcRI receptor) and B cells (e.g. via surface immunoglobulin molecules). Finally, it will be understood that the antibodies of the present invention might be used for disease treatment or prevention either alone or in combination with other molecules which potentiate the interaction with T-cells such as molecules which up-regulate class I and class-II MHC expression in certain cell types such as interferon-gamma or that the antibodies

of the present invention might themselves be used as vaccines through the inclusion of adjacent immunodominant B and T-cell epitopes optimally as multiple copies and targeted to professional antigen presenting cells.

It will be understood by those skilled in the art that immunodominant peptides might be included at many different locations in the antibody molecule via recombinant DNA or might alternatively be conjugated to the antibody molecule via natural amino acid residues or via amino acid residues incorporated by recombinant DNA for subsequent conjugation. It will be understood that incorporation or conjugation of these peptides should be such that, as required, antibody function such as binding affinity and rate of clearance is not impaired. Alternatively, it will be understood that peptides could be incorporated as part of an incomplete antibody fragment such as a Fab or Fv fragment. Depending on the application, it might be preferable to include the immunodominant peptides in a protein domain or structure designed to either mask the peptides from specific recognition by circulating or cell-bound molecules or to expose the peptides such that some immune recognition is possible instead of direct uptake by an internalising antigen. For peptides which particularly stimulate a good B-cell response following internalisation and presentation (particularly MHC class-II restricted), it might be preferable to mask the peptides from specific recognition by circulating antibodies in order to avoid premature clearance by the immune system. Finally, it will be understood that internalisation of immunodominant peptides might be achieved via a bispecific (or multispecific) antibody comprising at least one specificity for the internalising antigen and at

least one other specificity for the immunodominant peptide or peptide structure which is bound by the bispecific antibody prior to administration: in addition, it will be understood that a bivalent (or multivalent) antibody might be used consisting of one part binding to the internalising antigen and another part with no specific binding specificity but including the immunodominant peptide either within or attached to the antibody structure (including immunodominant peptides insertion at the usual sites for CDRs (complementarity-determining regions).

Figures 1 to 5 illustrate a number of possible designs for antibodies including immunodominant peptides either in discrete multi-peptide domains (figure 1 to 4) or as individual peptide sequences included to replace CDRs. These figures should not be considered an exclusive set of designs for antibodies containing immunodominant peptides and should not be considered as limiting the scope of the invention. In each case, antibodies are drawn comprising CDRs (complementarity-determining regions), VH and VL domains i.e. variable region heavy and light chain domains (including the CDRs), CL domains i.e. light chain constant domains, and CH1-3 i.e. heavy region constant domains.

Figure 1: this illustrates an antibody whereby the CH3 domain has been replaced by a domain including multiple copies of the same immunodominant peptide or, alternatively, individual copies of multiple peptides (for example, to compensate for MHC-restriction by providing a range of options covering different MHC haplotypes).

Figure 2: this illustrates an antibody whereby the immunodominant peptide domain has been fused adjacent to the hinge region in the heavy chains thus replacing the CH2 and CH3 domains.

Figure 3: this illustrates an antibody whereby the immunodominant peptide domain has been fused adjacent to the VL region in the light chains thus replacing the CL domains.

Figure 4: this illustrates a bispecific antibody created by either the coexpression or thiol reduction/oxidation of a mixture of antibody heavy chains whereby in one the immunodominant peptide domain has been fused adjacent to the hinge region thus replacing the CH2 and CH3 domains.

Figure 5: this illustrates an antibody whereby 6 copies (or 6 variants) of the immunodominant peptide have been inserted in the VH / VL regions to replace the CDRs.

The peptide domains referred to in figures 1 to 4 above could comprise either multiple repeats of the same immunodominant peptide or a range of different immunodominant peptide sequences within the same domain. In each case, the peptide sequences may be repeated in head-to-tail or head-to-head organisation with suitable amino acid spacing between the sequence repeats provided by non-immunodominant sequences. In each case, the immunodominant peptide

content of heavy and light chains might be the same or different and peptide domains may be added to one of only the heavy or light chains or in one of these chains only or as part of a bispecific (or multispecific) antibody whereby the peptide domains might only be derived from one or more of the recombinant chains used to create the bispecific. It will be understood that the arrangement of immunodominant peptide sequences in the peptide domain might require optimisation for different peptides included in the domain and might need to be optimised in order to ensure efficient production of the recombinant antibody without disruption of the antibody-like structure. It will also be understood that optimisation of antibodies for effective processing of the immunodominant peptide domains might also be required. In each case, optimisation might require different arrangements of peptides in conjunction with each other, different flanking amino acid sequences between the immunodominant peptides (including introduction of sequences to promote cleavage upon internal processing outside the immunodominant peptide regions) and different combinations with other peptide or protein structures as required for reasons such as to keep the total molecule from misfolding or to keep the immunodominant peptides either internalised or externalised in a globular protein structure.

The following examples serve to illustrate the possible applications of antibodies of the present invention and should not be considered as limiting the scope of the invention.

Example 1:

The generation of recombinant monoclonal antibodies suitable for use in treatment and prevention of human disease has been comprehensively described in the literature (for example Boulianne et al., Nature 312 (1984) p643, Morrison et al., PNAS 81 (1984) p6851, Riechmann et al., Nature 332 (1988) p323, Queen et al., PNAS (1989) p10029) and methods have been developed for production of whole antibodies from mammalian and other eucaryotic cells and also for production of antibody fragments (e.g. Fv or Fab fragments) from *E. coli*. For generation of antibodies from mammalian cells, all of the antibody designs depicted in figures 1 to 5 can be produced. Methods for generation of bispecific antibodies as depicted in figure 4 are also known in the art for mammalian cells and bispecific antibody fragments can also be generated from bacteria. In one example, the antibody of figure 1 could be generated to include tandem-repeated multiple copies of the CTL-inducing nonapeptides derived from the genes, MAGE-1, 2 and 3 (van den Eynde et al., Int J Cancer 44 (1989) p643) with suitable spacing provided by short runs of non-immunodominant amino acids between the immunodominant peptides. This could then be administered to a patient types as HLA-A1 harbouring a cancer with an internalising antigen (such as Lewis-Y) such that the antibody will internalise into the tumour and will potentially present the MAGE nonapeptides to the immune system. This may then activate MAGE-specific CTLs which will then lyse the tumour; alteratively, the patient could be preimmunised with MAGE peptides or an antibody such as in example 3 in order to expand and preactivate MAGE-specific CTLs.

Example 2:

As an alternative to example 1, antibodies could be generated in the same manner but containing class-II MHC restricted peptides such as the tetanus toxin peptide P2 (Panina-Bordignon et al., Eur. J. Immunol. 19, 1989, p2237) and administered to a cancer patient with an appropriate HLA-DR type for presentation of P2. If the antibody is again specific for an internalising antigen on the cancer cells, then the antibody will internalise into the tumour and will potentially present the P2 peptides to the immune system. This may then activate P2-specific T helper cells to release lymphokines and to activate B cells and also may activate CTLs which will then lyse the tumour; in addition, a greater antitumour response may be generated if the patient is preimmunised with P2 peptide or an antibody such as in example 3 in order to expand and preactivate P2-specific CTLs.

Example 3:

As alternatives to examples 1 and 2, antibodies could be generated in the same manner but with specificity for an internalising antigen on a professional antigen-presenting cells, such as specificity for surface-Ig on B cells, and including peptides presented by, for example cancer cells (e.g. for MAGE 1-3, a high proportion of human malignant melanoma cancers). If administered to a cancer patient with an appropriate MHC type for presentation of the peptides carried within the antibody, these should be processed and presented to the immune system by the antigen-presenting cells which would then stimulate an immune response against the cancer antigen represented by the peptides

presented. In addition, antibodies from examples 1 and 2 might be used in combination with the type of antibody of this example in order to efficiently present the antigen on the target cancer cells for effective activation of T cells.

Example 4:

As alternatives to examples 1 to 3, antibodies could be generated in the same manner for use in autoimmune diseases where the autoimmune immunodominant peptides are known. For example, T cells involved in the deterioration of normal tissue in the disease could be deleted or inhibited by creating an antibody specific for an internalising antigen on a professional antibody producing cell as in example 3 or by targeting the cells of the tissues subject to deterioration (e.g. thyroid cells via the TSH receptor for Graves Thyroiditis). In each case, the antibody would include multiple copies of the autoimmune immunodominant peptide to induce tolerance or would include altered peptides which, upon presentation, can bind to but not activate the deleterious T-cell thus inhibiting autoimmunity.



Fig 1:



Fig 2:

▨ MULTIPLE POLYPEPTIDE DOMAIN



Fig 3:



Fig 4:

MULTIPLE PEPTIDE DOMAIN



Fig 5 :

▨ SINGLE PEPTIDE DOMAINS